FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology.
FOXO Technologies Inc has announced that it...
Biotech AgeX leverages Juvenescence support to develop diabetes, regeneration and cancer research.
California-based AgeX Therapeutics, Inc, a biotech developing therapeutics for human aging and regeneration,...
The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement.
Over the coming weeks, we...
We dive into ChromaDex: the company behind the successful nicotinamide riboside supplement Tru Niagen®.
Over the coming weeks, we will be bringing you extracts of...
Biotech AgeX leverages Juvenescence support to develop diabetes, regeneration and cancer research.
California-based AgeX Therapeutics, Inc, a biotech developing therapeutics for human aging and regeneration,...
A fifth investor has joined UK Research and Innovation (UKRI), providing matched funding for top small innovators to develop ideas for healthy aging.
The new...
NervGen readies for NASDAQ listing and clinical trials of lead compound for nerve regeneration in 2021.
With a unique nerve regeneration technology, Canadian biotech NervGen...
Celeris bags €400k for creation of deep learning platform to support development of longevity drugs for Alzheimer's and other age-related diseases.
With a focus on...
Founding partner of 1843 Capital targets AgeTech investment opportunities with $13 million fund.
Connecticut-based early stage investment firm 1843 Capital values diversity highly, and seeks...
Wild Biotech plans to use database of more than 1,200 gut microbes to pursue novel drugs for human diseases and enhance CRISPR editing.
Wild Biotech,...
Clinical-stage gene therapy company announces $148 million raised in Series C financing for age-related macular degeneration.
London-based Gyroscope Therapeutics Limited, which focuses on treating diseases...
Longevity biotech exclusive Q&A with Cambrian Biopharma's CEO – hallmarks of aging and classifying aging as a disease.
Dr James Peyer is Cambrian's CEO and...
VitaDAO aims to extend human lifespan “by researching, financing, and commercializing longevity therapeutics in an open and democratic manner.”
An interesting new player has just...
Celeris bags €400k for creation of deep learning platform to support development of longevity drugs for Alzheimer's and other age-related diseases.
With a focus on...
McKenny-McFarlane Capital is focused on bridging the communication gap between longevity investing and longevity companies.
An investment firm with its sights firmly locked on longevity...
Digital health and wellness company bags $7 million in seed funding led by Andreessen Horowitz.
Bold focuses on disease prevention and healthy aging. Using personalised and...
Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine.
In the first part of...
Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism.
The role of the thyroid gland is...
EU Green Paper on Ageing is a wish list, but the European Longevity Initiative is proposing a foundation first.
Back in January, the European Commission...
Determined to bring longevity opportunities to a wider market, JUVICELL packs ten ingredients into its longevity supplement.
Over the coming weeks, we will be bringing...
Can biological age be set back by "making the clock tick backwards"? Scientists suggest that a partial phenotypic rejuvenation can be gained.
Since the discovery...
